Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma (PRadR2)
PRadR2 - A Single Center, Open-label, Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma
This study is an open label, Phase I study investigating the safety and clinical activity of 4 IV injections of 161Tb-PSMA-1 in patients with mccRCC.
This trial is divided in 2 parts:
- The dose escalation part aims to assess the safety of 161Tb-PSMA-1 in up to 21 patients with mccRCC. Eligible patients will be treated with escalating activity of 161Tb-PSMA.
- The extension part aims to collect preliminary clinical activity data of the proposed treatment.
研究概览
详细说明
Patients with mccRCC will be selected, treated and followed-up as described below:
Selection step - 68Ga-PSMA PET:
A selection step at screening is mandatory for all patients in order to evaluate the PSMA expression in tumor lesions through 68Ga-PSMA PET and according to local imaging review. Only patients with PSMA expressing tumors according to eligibility criteria define din the protocol will be eligible to the treatment step.
Treatment step:
Eligible patients will be treated with escalating doses of 161Tb-PSMA-1 (from 7.4 GBq ± 10% to 11.5GBq ± 10%), intravenously (IV) for 4 cycles administered every 6 weeks. Three DL are expected to be assessed in the dose escalation part from 7.4 to 11.5 GBq ± 10%.
Dose Levels 161Tb-PSMA, IV, Q6W, 4 doses :
- DL-1 5.5 GBq ± 10% Q6W
- DL1 (starting activity) 7.4 GBq ± 10% Q6W
- DL2 9.5 GBq ± 10% Q6W
- DL3 11.5 GBq ± 10% Q6W
Assessment step:
To assess tumor response according to RECIST V1.1, imaging will be performed at baseline, W9-10, W24, then every 12 weeks up to 1 year after the first administration and every 24 weeks afterwards until progression, death or overall study completion, whichever is earliest. Survival status will be documented for all patients until death or overall study completion at least 12 months after the last patient. Moreover, to study the distribution of the 161Tb-PSMA-1 in standard organs and tumor lesions, repeated SPECT-CT acquisitions will be performed on all patients treated in the dose escalation part.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Anne-Laure GIRAUDET, MD
- 电话号码:04 78 78 20 21
- 邮箱:anne-laure.giraudet@lyon.unicancer.fr
学习地点
-
-
-
Lyon、法国、69737
- Centre Léon Bérard
-
副研究员:
- Armelle VINCENEUX, MD
-
接触:
- Anne-Laure GIRAUDET, MD
- 电话号码:04 78 78 20 21
- 邮箱:annelaure.giraudet@lyon.unicancer.fr
-
接触:
- Armelle VINCENEUX, MD
- 电话号码:04 26 55 68 33
- 邮箱:armelle.vinceneux@lyon.unicancer.fr
-
首席研究员:
- Anne-Laure GIRAUDET, MD
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- I1. Male or female patients aged ≥ 18 years at time of informed consent signature.
- I2. Patient with histologically confirmed diagnosis of metastatic clear cell renal cell carcinoma (mccRCC) progressing during or after at least 2 lines of therapy including at least 1 line of anti-VEGFR and 1 line of immunotherapy.
- I3. Patient with documented radiological disease progression at the time of inclusion with measurable disease as per RECIST v1.1.
I4. Patient with positive PSMA-PET (68Ga-PSMA-PET) (see Appendix 6):
- For patient with only extrahepatic disease: ≥ 50% of positive extrahepatic lesions
- For patient with both extra-hepatic and liver metastasis: ≥ 50% of positive extrahepatic metastatic lesions and ≥ 80 % of positive supracentimetric liver metastatic lesions.
- For patient with only liver metastatic lesions: ≥ 80 % of positive supracentimetric lesions
- I5. Life expectancy ≥ 6 months.
- I6. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, with a Karnofsky Performance Status (KPS) ≥ 80%.
- I7. Adequate organ function according to laboratory values defined below:
Haematological function :
- Peripheral absolute neutrophil count (ANC) ≥1.5 x 109 /L
- Platelet count ≥ 100 x 109/L
- Hemoglobin ≥ 9.0 g/dL (without transfusion within 7 days)
Renal and hepatic function :
Serum creatinine or creatinine clearance according to CKD-EPI
o ≤ 1.5 X upper limit of normal (ULN) OR ≥ 40 mL/min/1.73m2
Total bilirubin
o ≤ 1.5 X ULN with the following exception: Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be enrolled
Aspartate aminotransferase (ASAT) and Alanine aminotransferase (ALAT) ≤ 1.5 X ULN (up to 3x ULN in case of liver metastases)
- I8. Women of child-bearing potential must have a negative pregnancy test at screening (within 72 hours prior C1D1) and must agree to use 1 highly effective form of contraception from the time of the treatment period and of the negative pregnancy test up to 6 months after the last administration of IMP. Effective forms of contraception are listed in Appendix 5.
- I9. Fertile males must use a highly effective contraception during dosing period and through 6 months after final administration of study.
- I10. Patient should be able and willing to comply with study visits and procedures as per protocol.
- I11. Patient should understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures performed.
- I12. Covered by a medical insurance.
Exclusion Criteria:
- E1. Patients with known active central nervous system (CNS) metastases and/or epidural metastases and/or leptomeningitis. Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to C1D1 and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids (at doses higher than 10 mg/d of methylprednisolone or equivalent) for at least 4 weeks prior to C1D1.
- E2. Patients previously treated with any radiopharmaceutical.
- E3. Persisting AEs related to previous anti-cancer therapy which were not resolved to grade ≤ 1 (except: anemia provided that criterion I7 is met) and /or any persistent immune-related AEs >1 (except adequately controlled irAE, e.g.: with replacement therapy for endocrine irAE) using NCI CTCAE V6.0.
- E4. History, within 2 years, of cancer other than renal cancer, except for basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or localized prostate cancer.
- E5. History of idiopathic pulmonary fibrosis, non-infectious pneumonitis, interstitial lung disease that required steroids or has current pneumonitis, interstitial lung disease, drug-induced pneumonitis, or evidence of active pneumonitis.
- E6. Prior therapy or needs to be treated with a forbidden concomitant/concurrent therapies/procedures including (see protocol for minimal wash out period to C1D1 and use during treatment) :
- Any anticancer treatment (immunotherapy, chemotherapy) or investigational therapy
- Targeted therapy including antiangiogenic therapy
- Radiotherapy
- Major surgery
- Growth factors targeting the myeloid lineage (e.g., G-CSF, GM-CSF, M-CSF) or growth factors targeting the erythroid lineage (e.g., erythropoietin)
- Live or live-attenuated vaccine. Note: killed vaccines are allowed.
- E7. Patients with clinically significant hematuria, hematemesis or hemoptysis exceeding 0.5 teaspoon (2.5mL) of red blood, as well as those with a history of coagulopathy or other significant bleeding (e.g., pulmonary hemorrhage) within the 3 months prior to the initiation of the study treatment. Patients receiving anticoagulation medication will be eligible only if the dosage and route of administration have remained stable for at least 2 weeks prior to C1D1.
- E8. Patients with an active uncontrolled infection.
- E9. Pregnant or breastfeeding women.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:161Tb-PSMA-1
Radiopharmaceutical - injectable solution
|
161Tb-PSMA-1 (from 7.4 GBq ± 10% to 11.5GBq ± 10%), intravenously (IV) for 4 cycles administered every 6 weeks. Dose Levels 161Tb-PSMA, IV, Q6W, 4 doses
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Incidence of Dose-limiting toxicities (DLT)
大体时间:During the first cycle of treatment (i.e., first 6 weeks)
|
During the first cycle of treatment (i.e., first 6 weeks)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective Response Rate at 24 weeks (ORR-24W)
大体时间:24 weeks after treatment start
|
24 weeks after treatment start
|
|
|
Objective Response Rate (ORR)
大体时间:Assessed through study completion, an average of 12 months.
|
defined as the rate of patients with a complete or partial response (CR or PR) according to RECIST v1.1.
|
Assessed through study completion, an average of 12 months.
|
|
Disease Control Rate after 24 weeks (DCR24w)
大体时间:24 weeks after treatment start
|
24 weeks after treatment start
|
|
|
Best Overall Response Rate (BORR)
大体时间:Assessed through study completion, an average of 12 months.
|
Assessed through study completion, an average of 12 months.
|
|
|
Duration of response (DOR)
大体时间:From the date of first documented response until date of documented progression per RECIST 1.1 or death due to any cause, assessed through study completion, an average of 12 months.
|
From the date of first documented response until date of documented progression per RECIST 1.1 or death due to any cause, assessed through study completion, an average of 12 months.
|
|
|
Progression Free Survival (PFS)
大体时间:From treatment start until the date of documented progression or death due to any cause, assessed through study completion, an average of 12 months.
|
From treatment start until the date of documented progression or death due to any cause, assessed through study completion, an average of 12 months.
|
|
|
Overall Survival (OS)
大体时间:From treatment start to the date of death, assessed through study completion, an average of 12 months.
|
From treatment start to the date of death, assessed through study completion, an average of 12 months.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.